Clinical and adverse effect profiles of paediatric polypharmacy by gender and ADHD status
Kastamonu Medical Journal · 12.03.2026 · 6 (1) · 64-71
DOI: 10.66235/kumj.1906761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kastamonu Medical Journal, online erschienen am 12.03.2026. Verfasst von Yusuf Selman Çelik und 6 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Aims
This study aims to investigate the prevalence of concurrent psychotropic polypharmacy systematically, its associated adverse effects, and their relationship with individual factors such as diagnosis and gender in a child and adolescent outpatient population. While most existing literature on polypharmacy focuses on adults, there is a lack of recent, field-based data concerning children and adolescents.
Methods
Among 4,928 outpatient admissions in January 2024, 595 children receiving two or more concurrent psychotropic medications were included. Polypharmacy was operationalized as the concurrent use of two or more psychotropic medication classes for a minimum duration of 30 consecutive days, consistent with thresholds described in previous guidelines (e.g., AACAP, NICE). Over a six-month follow-up, diagnostic profiles, medication regimens, comorbidities, adverse effects, and adherence were evaluated using clinical records and national e-Nabız data.
Results
The sample was 57.1% male, with a median age of 13. Polypharmacy was most common among 16–18-year-olds. ADHD (52.8%), generalized anxiety disorder (19.5%), and depression/dysthymia (9.2%) were the most frequent diagnoses. Comorbidity was present in 76.6% of cases. Anxiety and mood disorders were more common in females, whereas specific learning disorder and enuresis were more prevalent in males. Stimulant-antipsychotic combinations were more typical in males; antidepressant-antipsychotic combinations were more common in females. Reported adverse effects included sleep disturbances, appetite changes, and irritability, with no significant differences between medication groups.
Conclusion
Polypharmacy was more frequent in adolescents and those with ADHD, anxiety, or depression. Gender differences in medication patterns likely reflect underlying psychopathology. Given the high rates of adverse effects, structured monitoring protocols, including sleep and appetite checklists, should be routinely implemented. The findings support the integration of scheduled medication reviews and age- and gender-sensitive pharmacotherapy planning in child and adolescent psychiatry.
Zitieren
APA
Çelik, Y. S., Solgun, G., Karakolcu, S. N., Şahin, B., Duru, N., Demirtaş, E. N. Ş., & Kaşak, M. (2026). Clinical and adverse effect profiles of paediatric polypharmacy by gender and ADHD status. Kastamonu Medical Journal, 6(1), 64-71. https://doi.org/10.66235/kumj.1906761
Vancouver
Çelik YS, Solgun G, Karakolcu SN, Şahin B, Duru N, Demirtaş ENŞ, et al. Clinical and adverse effect profiles of paediatric polypharmacy by gender and ADHD status. Kastamonu Medical Journal. 2026;6(1):64-71. doi:10.66235/kumj.1906761
BibTeX
@article{elik2026,
author = {Çelik, Yusuf Selman and Solgun, Görkem and Karakolcu, Sidre Nur and Şahin, Berkay and Duru, Nur and Demirtaş, Elif Nur Şen and Kaşak, Meryem},
title = {Clinical and adverse effect profiles of paediatric polypharmacy by gender and ADHD status},
journal = {Kastamonu Medical Journal},
year = {2026},
volume = {6},
number = {1},
pages = {64--71},
doi = {10.66235/kumj.1906761}
}
EUVIMED